DAPA-HF Published:'Stunning Consistent Benefit With Dapagliflozin'DAPA-HF Published:'Stunning Consistent Benefit With Dapagliflozin '
Publication of trial reinforces"remarkably consistent" benefits of the SGLT2 inhibitor dapagliflozin in patients with heart failure, with or without diabetes,"bolsters confidence in the conclusions."Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
' Strongest Evidence Yet' That Diabetes Drugs Are Renoprotective'Strongest Evidence Yet' That Diabetes Drugs Are Renoprotective
Meta-analysis of four major trials in patients with type 2 diabetes shows significant renal benefit of SGLT2 inhibitors, even in patients with reduced kidney function.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 12, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
SGLT2 inhibitors may help prevent kidney failure
A study published in theLancet Diabetes and Endocrinology has found SGLT2 inhibitors, taken to lower blood glucose levels, prevent loss of kidney function and kidney failure in people with type 2 diabetes.MedicalXpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - September 6, 2019 Category: Endocrinology Source Type: news
Will DAPA-HF Turn the Tide on Heart Failure? Will DAPA-HF Turn the Tide on Heart Failure?
The term gamechanger is overused but may be appropriate for the DAPA-HF trial on the SGLT2 inhibitor dapagliflozin in patients with heart failure and reduced ejection fraction. Medical conservative John Mandrola, MD, was impressed.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 6, 2019 Category: Cardiology Tags: Cardiology Expert Column Source Type: news
SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis
SGLT2 inhibitors are commonly used in the treatment of type 2 diabetes, but might their use also contribute to the potential development of diabetic ketoacidosis?Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 6, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Cardiologists Should Prescribe SGLT2 Inhibitors Cardiologists Should Prescribe SGLT2 Inhibitors
Is it fair to expect cardiologists to now prescribe the new diabetes drugs? Presentations at the European Society of Cardiology Congress prove persuasive to Melissa Walton-Shirley, MD.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 5, 2019 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news
Newer diabetes drug drops heart failure risk by 34 percent, study says
Newer drugs for type 2 diabetes called SGLT2 inhibitors may also have a beneficial side effect for cardiovascular health, with a study showing they can reduce heart failure risk by 34 percent. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 29, 2019 Category: Consumer Health News Source Type: news
DAPA-HF Top-Line Results: Dapagliflozin Hits Primary Outcome DAPA-HF Top-Line Results: Dapagliflozin Hits Primary Outcome
The SGLT2 inhibitor dapagliflozin provided significant and clinically meaningful reductions in heart failure outcomes, according to the sponsoring company.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 20, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
' Reassuring': New Type 2 Diabetes Drugs Not Linked to UTIs'Reassuring': New Type 2 Diabetes Drugs Not Linked to UTIs
Analyses from 2 large databases find no greater risk for urinary tract infections with one kind of new type 2 diabetes agent, SGLT2 inhibitors, compared with DPP4 inhibitors or GLP1 receptor agonists.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - July 29, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Periop Diabetic Ketoacidosis Seen in Patients on SGLT2 Inhibitors
WEDNESDAY, July 24, 2019 -- Sodium-glucose cotransporter-2 inhibitor (SGLT2i)-associated diabetic ketoacidosis (DKA) may occur after surgery even in patients with normal or near-normal blood glucose levels, according to a review published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 24, 2019 Category: Pharmaceuticals Source Type: news
Fournier Gangrene, Genitourinary Infection With SGLT2i: ADA 2019 Fournier Gangrene, Genitourinary Infection With SGLT2i: ADA 2019
SGLT2 inhibitors carry warnings about Fournier gangrene (a necrotizing fasciitis of the genitalia), genital fungal infections, and UTIs. What new data were presented at the 2019 American Diabetes Association meeting?Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - July 18, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology Article Source Type: news
No Fracture Risk for New Diabetes Drugs in Real-World Study No Fracture Risk for New Diabetes Drugs in Real-World Study
Link between SGLT2 inhibitors for type 2 diabetes and fractures has been controversial. Canagliflozin has an FDA warning about the risk, but some studies have found no link.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - July 17, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
How Do the Renal Data From CREDENCE and CARMELINA Compare? How Do the Renal Data From CREDENCE and CARMELINA Compare?
Meg Jardine and Christoph Wanner, investigators from the CREDENCE and CARMELINA trials, respectively, discuss the implications for SGLT2 inhibitor and DPP-4 inhibitor use in patients with kidney disease.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 26, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news
Diabetes treatment does not increase risk of bone fracture
According to a recent study inOsteoporosis International, antidiabetic therapies, GLP-1 agonists, SGLT2 inhibitors and DPP-IV inhibitors, do not increase the risk of bone fractures in patients with type 2 diabetes.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 18, 2019 Category: Endocrinology Source Type: news
CREDENCE'Knocks Your Socks Off'; New Analysis Reported at ADA CREDENCE'Knocks Your Socks Off'; New Analysis Reported at ADA
Latest analysis of CREDENCE with SGLT2 inhibitor canagliflozin shows the agent has a cardio- and renal-protective effect in both primary and secondary CV prevention populations.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - June 17, 2019 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news
